Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX07 in Advanced Hepatocellular Carcinoma
NCT05290220Phase 2Unknown
- Sponsor
- Henlius
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of pimurutamab in hepatocellular carcinoma (HCC), sponsored by Henlius. Status: unknown.
02
Drugs
pimurutamab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05290220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05290220.